PTCT
PTC Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
PTC Therapeutics has 9 disclosed suppliers and 4 disclosed customers in SEC filings.
SentencePursuant to the Tegsedi-Waylivra Agreement, we have entered into a master supply agreement with Akcea whereby Akcea or its affiliates will manufacture and supply, or cause to be manufactured and supplied, Tegsedi and Waylivra in quantities sufficient to support the commercialization of Tegsedi and Waylivra in the PTC Territory.
PTCT 10-Kaccession 0001104659-26-017575
SentenceUnder an Exclusive License and Supply Agreement, or the Faes Agreement, with Faes Farma, S.A., or Faes, we are required to pay royalties as a percentage of or as a fixed payment with respect to net product sales by us allocable to the Emflaza oral suspension product.
PTCT 10-Kaccession 0001104659-26-017575
SentenceThe decrease was primarily due to decreases in royalty costs driven by Emflaza as a result of the completion of the royalty agreement with Marathon Pharmaceuticals, LLC (now known as Complete Pharma Holdings, LLC), which was partially offset by costs associated with the Novartis Agreement, inventory costs associated with the Sephience launch, Upstaza/Kebilidi and Sephience royalty payments, an increase in inventory reserves, and costs associated with new product sales.
PTCT 10-Kaccession 0001104659-26-017575
SentenceWe have a commercial manufacturing services agreement with MassBiologics of the University of Massachusetts Medical School, or MassBio, to provide sufficient quantities of our Upstaza/Kebilidi materials to meet commercial scale demands.
PTCT 10-Kaccession 0001104659-26-017575
SentencePursuant to the license and technology transfer agreement, originally entered into between Agilis Biotherapeutics, Inc., or Agilis, NTU and Professor Wuh-Liang (Paul) Hwu, in December 2015, or the NTU Licensing Agreement, NTU granted to us an exclusive, perpetual license, with the right to grant sublicenses through all tiers, to research and use the intellectual property, data, chemistry, manufacturing and controls, or CMC, records, documents, confidential information, materials and know-how pertaining to the Research, including Upstaza for the treatment of AADC deficiency, under the NTU Collaboration Agreement (as defined below), or the Technology, and to develop, make, manufacture, use, sell, import and market the Technology and any other products made, invented, developed or incorporated by or with the Technology, or the Licensed Products.
PTCT 10-Kaccession 0001104659-26-017575
SentenceUnder the Shiratori License Agreement, we are obligated to pay to Shiratori a low single digit percentage of annual net sales of the Sepiapterin Products in each country in the Sepiapterin Territory until the expiration of the last-to-expire Licensed Patent controlled by Shiratori covering the relevant country followed by an obligation to pay a reduced royalty rate for a specified period of time thereafter.
PTCT 10-Kaccession 0001104659-26-017575
SentenceSince inception, the SMA Foundation has earned $52.5 million, all of which was paid as of December 31, 2025.
PTCT 10-Kaccession 0001104659-26-017575
SentenceUnder the Novartis Agreement, and upon the closing of the transaction contemplated by the Novartis Agreement in January 2025, we received an upfront payment of $1.0 billion on the effective date and can receive up to $1.9 billion in development, regulatory and sales milestones, a 40% share of U.S. profits and losses, and tiered double-digit royalties on ex-U.S. sales.
SentenceFor example, we make sales of Translarna through a distributor to the Ministry of Health of the Russian Federation to access Russian nmDMD patients.
PTCT 10-Kaccession 0001104659-26-017575
SentenceWe are eligible to receive additional payments from Roche if specified events are achieved with respect to each licensed product, including up to $135.0 million in research and development event milestones, up to $325.0 million in sales milestones upon achievement of specified sales events, and up to double digit royalties on worldwide annual net sales of a commercial product.
PTCT 10-Kaccession 0001104659-26-017575
SentenceTo date, Royalty Pharma has paid to us cash consideration of $2.1 billion in exchange for 100% of the Royalty.
PTCT 10-Kaccession 0001104659-26-017575
Last report3 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−6.97%
vs ±12.0% implied · ×0.58
shaded = implied · ▲▼ = realized
Linked news
PTC Therapeutics, Inc.
59.94
−4.52 · −7.01%
post 59.99 +0.08%
Expected move
Inputsspot 59.97exp Jan 15ATM strike 60ATM straddle 11.55IV 53%